PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 14691070-1 2004 AIMS: Cholecystokinin (CCK), one of the most abundant neurotransmitter peptides, interacts with dopamine. Dopamine 96-104 cholecystokinin Homo sapiens 6-21 14691070-1 2004 AIMS: Cholecystokinin (CCK), one of the most abundant neurotransmitter peptides, interacts with dopamine. Dopamine 96-104 cholecystokinin Homo sapiens 23-26 14691070-3 2004 CCK modulates dopamine release in the nucleus accumbens via the CCK-A receptor (R). Dopamine 14-22 cholecystokinin Homo sapiens 0-3 11967633-1 2002 RATIONALE: Cholecystokinin (CCK) is a neuropeptide which is colocalized with dopamine (DA) in neurons of the mesolimbic-frontocortical and nigrostriatal DA system. Dopamine 87-89 cholecystokinin Homo sapiens 28-31 12790157-2 2003 This paper focuses on the role of CCK in modulating anxiety-related and reward-related behaviours in key brain regions of the amygdala and mesolimbic dopamine system, respectively. Dopamine 150-158 cholecystokinin Homo sapiens 34-37 11967633-1 2002 RATIONALE: Cholecystokinin (CCK) is a neuropeptide which is colocalized with dopamine (DA) in neurons of the mesolimbic-frontocortical and nigrostriatal DA system. Dopamine 77-85 cholecystokinin Homo sapiens 11-26 12777967-1 2003 Cholecystokinin modulates the release of dopamine and dopamine-related behaviours in the mesolimbic pathway, where cholecystokinin and dopamine coexist in dopaminergic neurones. Dopamine 41-49 cholecystokinin Homo sapiens 115-130 12777967-1 2003 Cholecystokinin modulates the release of dopamine and dopamine-related behaviours in the mesolimbic pathway, where cholecystokinin and dopamine coexist in dopaminergic neurones. Dopamine 54-62 cholecystokinin Homo sapiens 115-130 12777967-1 2003 Cholecystokinin modulates the release of dopamine and dopamine-related behaviours in the mesolimbic pathway, where cholecystokinin and dopamine coexist in dopaminergic neurones. Dopamine 54-62 cholecystokinin Homo sapiens 115-130 12424552-1 2002 RATIONALE: Converging evidence has demonstrated that cholecystokinin (CCK) inhibits mesolimbic brain dopamine (DA) function via activation of CCK-A (CCK-1) receptors. Dopamine 101-109 cholecystokinin Homo sapiens 53-68 12424552-1 2002 RATIONALE: Converging evidence has demonstrated that cholecystokinin (CCK) inhibits mesolimbic brain dopamine (DA) function via activation of CCK-A (CCK-1) receptors. Dopamine 101-109 cholecystokinin Homo sapiens 70-73 12198366-1 2002 BACKGROUND: Cholecystokinin (CCK) plays an important role in the function of the central nervous system by interacting with dopamine and other neurotransmitters. Dopamine 124-132 cholecystokinin Homo sapiens 12-27 12198366-1 2002 BACKGROUND: Cholecystokinin (CCK) plays an important role in the function of the central nervous system by interacting with dopamine and other neurotransmitters. Dopamine 124-132 cholecystokinin Homo sapiens 29-32 11967633-1 2002 RATIONALE: Cholecystokinin (CCK) is a neuropeptide which is colocalized with dopamine (DA) in neurons of the mesolimbic-frontocortical and nigrostriatal DA system. Dopamine 77-85 cholecystokinin Homo sapiens 28-31 11967633-1 2002 RATIONALE: Cholecystokinin (CCK) is a neuropeptide which is colocalized with dopamine (DA) in neurons of the mesolimbic-frontocortical and nigrostriatal DA system. Dopamine 87-89 cholecystokinin Homo sapiens 11-26 11967633-1 2002 RATIONALE: Cholecystokinin (CCK) is a neuropeptide which is colocalized with dopamine (DA) in neurons of the mesolimbic-frontocortical and nigrostriatal DA system. Dopamine 153-155 cholecystokinin Homo sapiens 11-26 11967633-1 2002 RATIONALE: Cholecystokinin (CCK) is a neuropeptide which is colocalized with dopamine (DA) in neurons of the mesolimbic-frontocortical and nigrostriatal DA system. Dopamine 153-155 cholecystokinin Homo sapiens 28-31 11967633-2 2002 In animals CCK enhances DA activity in these systems. Dopamine 24-26 cholecystokinin Homo sapiens 11-14 11513220-1 2001 OBJECTIVE: Cholecystokinin (CCK) plays an important role in the functioning of the central nervous system via an interaction with dopamine and other neurotransmitters. Dopamine 130-138 cholecystokinin Homo sapiens 28-31 11513220-1 2001 OBJECTIVE: Cholecystokinin (CCK) plays an important role in the functioning of the central nervous system via an interaction with dopamine and other neurotransmitters. Dopamine 130-138 cholecystokinin Homo sapiens 11-26 12116760-2 2002 Particular emphasis is laid on the modulating influence of CCK on dopamine neuromediation in the mesolymbic structures of the brain, which are linked with the regulation of emotions and craving. Dopamine 66-74 cholecystokinin Homo sapiens 59-62 12116760-5 2002 The designed new tetrapeptide, a CCK analogue, selectively inhibits anxiety in animals with this emotional disorder, which is followed by normalization of dopamine exchange and GABA-system functions. Dopamine 155-163 cholecystokinin Homo sapiens 33-36 12116760-6 2002 It is concluded that by interacting with the dopamine-system, CCK takes a direct part in the regulation of emotions and craving. Dopamine 45-53 cholecystokinin Homo sapiens 62-65 11549403-1 2001 Cholecystokinin A receptors (CCKAR) modulate CCK-stimulated dopamine release, and mutations in the CCKAR gene may predispose affected individuals to schizophrenia. Dopamine 60-68 cholecystokinin Homo sapiens 29-32 10893485-1 2000 The cholecystokinin A receptor (CCK-AR) modulates CCK-stimulated dopamine release in the posterior nucleus accumbens, and its gene is mapped to 4p15.2-15.1 with the dopamine receptor 5 (DR5) gene. Dopamine 65-73 cholecystokinin Homo sapiens 32-35 9663451-1 1998 Behavioral and pharmacological evidence has shown a different and opposite role of the neuropeptide cholecystokinin (CCK) on the dopamine (DA) function in the caudal versus rostral part of the nucleus accumbens. Dopamine 129-137 cholecystokinin Homo sapiens 117-120 10220011-2 1999 Cholecystokinin (CCK) co-exists in a large proportion of A10 dopamine neurons to exert some effect on dopamine-induced behavior. Dopamine 61-69 cholecystokinin Homo sapiens 0-15 10220011-2 1999 Cholecystokinin (CCK) co-exists in a large proportion of A10 dopamine neurons to exert some effect on dopamine-induced behavior. Dopamine 61-69 cholecystokinin Homo sapiens 17-20 10220011-2 1999 Cholecystokinin (CCK) co-exists in a large proportion of A10 dopamine neurons to exert some effect on dopamine-induced behavior. Dopamine 102-110 cholecystokinin Homo sapiens 0-15 10220011-2 1999 Cholecystokinin (CCK) co-exists in a large proportion of A10 dopamine neurons to exert some effect on dopamine-induced behavior. Dopamine 102-110 cholecystokinin Homo sapiens 17-20 9885794-1 1999 Systemic injections of cholecystokinin (CCK), a "gut-brain" peptide, have been shown to modulate brain dopamine function and produce neuroleptic-like effects on such dopamine-regulated behaviors as locomotor activity. Dopamine 103-111 cholecystokinin Homo sapiens 23-38 9885794-1 1999 Systemic injections of cholecystokinin (CCK), a "gut-brain" peptide, have been shown to modulate brain dopamine function and produce neuroleptic-like effects on such dopamine-regulated behaviors as locomotor activity. Dopamine 103-111 cholecystokinin Homo sapiens 40-43 9885794-1 1999 Systemic injections of cholecystokinin (CCK), a "gut-brain" peptide, have been shown to modulate brain dopamine function and produce neuroleptic-like effects on such dopamine-regulated behaviors as locomotor activity. Dopamine 166-174 cholecystokinin Homo sapiens 23-38 9885794-1 1999 Systemic injections of cholecystokinin (CCK), a "gut-brain" peptide, have been shown to modulate brain dopamine function and produce neuroleptic-like effects on such dopamine-regulated behaviors as locomotor activity. Dopamine 166-174 cholecystokinin Homo sapiens 40-43 10803770-1 2000 BACKGROUND: Cholecystokinin (CCK) is considered to play an important role in the central nervous system via its interaction with other neurotransmitters such as dopamine, serotonin, gamma-aminobutyric acid, substance P, and enkephalins. Dopamine 161-169 cholecystokinin Homo sapiens 12-27 10803770-1 2000 BACKGROUND: Cholecystokinin (CCK) is considered to play an important role in the central nervous system via its interaction with other neurotransmitters such as dopamine, serotonin, gamma-aminobutyric acid, substance P, and enkephalins. Dopamine 161-169 cholecystokinin Homo sapiens 29-32 10668930-3 1999 Cholecystokinin (CCK) modulates the release of dopamine in the mesolimbic pathway and affects dopamine-related behavior. Dopamine 47-55 cholecystokinin Homo sapiens 17-20 10668930-3 1999 Cholecystokinin (CCK) modulates the release of dopamine in the mesolimbic pathway and affects dopamine-related behavior. Dopamine 94-102 cholecystokinin Homo sapiens 17-20 10235270-1 1999 In the central nervous system, cholecystokinin (CCK) is an important neurotransmitter that gives the influences on firings, anxiety, notiception, and dopamine-related behavior. Dopamine 150-158 cholecystokinin Homo sapiens 31-46 10235270-1 1999 In the central nervous system, cholecystokinin (CCK) is an important neurotransmitter that gives the influences on firings, anxiety, notiception, and dopamine-related behavior. Dopamine 150-158 cholecystokinin Homo sapiens 48-51 10235270-2 1999 CCK co-exists in the dopaminergic neurons, interacting with dopamine. Dopamine 21-29 cholecystokinin Homo sapiens 0-3 15616622-6 1998 The obvious neuroanatomical association between dopamine and CCK continues to stimulate research directed towards the development of new antipsychotic drugs. Dopamine 48-56 cholecystokinin Homo sapiens 61-64 9622381-2 1998 Furthermore, CCK modulates the release of dopamine and dopamine-related behaviors in the mesolimbic pathway. Dopamine 42-50 cholecystokinin Homo sapiens 13-16 9622381-2 1998 Furthermore, CCK modulates the release of dopamine and dopamine-related behaviors in the mesolimbic pathway. Dopamine 55-63 cholecystokinin Homo sapiens 13-16 9663451-1 1998 Behavioral and pharmacological evidence has shown a different and opposite role of the neuropeptide cholecystokinin (CCK) on the dopamine (DA) function in the caudal versus rostral part of the nucleus accumbens. Dopamine 139-141 cholecystokinin Homo sapiens 117-120 9663451-7 1998 These data constitute the first neuroanatomical evidence for the differential effects of CCK on dopamine actions in the different regions of the nucleus accumbens. Dopamine 96-104 cholecystokinin Homo sapiens 89-92 8748063-3 1995 CCK participates in the mediation of satiety; it interacts with dopamine and may modulate psychosis; it interacts with opiate systems and may be an "anti-analgesic": and it appears to play a role in the mediation of anxiety. Dopamine 64-72 cholecystokinin Homo sapiens 0-3 8951986-1 1996 Cholecystokinin (CCK) is an endogenous peptide that is colocalized with dopamine (DA) in some mesolimbic neurons projecting to the nucleus accumbens (NAC). Dopamine 72-80 cholecystokinin Homo sapiens 0-15 8951986-1 1996 Cholecystokinin (CCK) is an endogenous peptide that is colocalized with dopamine (DA) in some mesolimbic neurons projecting to the nucleus accumbens (NAC). Dopamine 72-80 cholecystokinin Homo sapiens 17-20 8951986-1 1996 Cholecystokinin (CCK) is an endogenous peptide that is colocalized with dopamine (DA) in some mesolimbic neurons projecting to the nucleus accumbens (NAC). Dopamine 82-84 cholecystokinin Homo sapiens 0-15 8951986-1 1996 Cholecystokinin (CCK) is an endogenous peptide that is colocalized with dopamine (DA) in some mesolimbic neurons projecting to the nucleus accumbens (NAC). Dopamine 82-84 cholecystokinin Homo sapiens 17-20 8951986-3 1996 A variety of experimental evidence suggests that exogenously applied CCK, acting at the CCKA receptor, potentiates the function of DA in the NAC. Dopamine 131-133 cholecystokinin Homo sapiens 69-72 8761988-1 1996 Cholecystokinin (CCK) has been localized in the nucleus accumbens (NAC) where it may interact with dopamine neurotransmission. Dopamine 99-107 cholecystokinin Homo sapiens 0-15 8761988-1 1996 Cholecystokinin (CCK) has been localized in the nucleus accumbens (NAC) where it may interact with dopamine neurotransmission. Dopamine 99-107 cholecystokinin Homo sapiens 17-20 9574843-0 1997 Cholecystokinin increases extracellular dopamine overflow in the anterior nucleus accumbens via CCK(B) receptors in the VTA assessed by in vivo voltammetry. Dopamine 40-48 cholecystokinin Homo sapiens 0-15 9574843-0 1997 Cholecystokinin increases extracellular dopamine overflow in the anterior nucleus accumbens via CCK(B) receptors in the VTA assessed by in vivo voltammetry. Dopamine 40-48 cholecystokinin Homo sapiens 96-99 7491953-2 1995 CCK and its receptors are also widely distributed in the central nervous system (CNS) and contribute to the regulation of satiety, anxiety, analgesia, and dopamine-mediated behavior. Dopamine 155-163 cholecystokinin Homo sapiens 0-3 7914685-0 1994 Nucleus accumbens dopamine-CCK interactions in psychostimulant reward and related behaviors. Dopamine 18-26 cholecystokinin Homo sapiens 27-30 7640325-1 1995 Cholecystokinin (CCK) is co-localized with dopamine (DA) in neurons of the mesolimbic-frontocortical dopamine (DA) system, considered essential for the pathology of psychotic behavior and associated attention deficits. Dopamine 43-51 cholecystokinin Homo sapiens 0-15 7640325-1 1995 Cholecystokinin (CCK) is co-localized with dopamine (DA) in neurons of the mesolimbic-frontocortical dopamine (DA) system, considered essential for the pathology of psychotic behavior and associated attention deficits. Dopamine 43-51 cholecystokinin Homo sapiens 17-20 7640325-1 1995 Cholecystokinin (CCK) is co-localized with dopamine (DA) in neurons of the mesolimbic-frontocortical dopamine (DA) system, considered essential for the pathology of psychotic behavior and associated attention deficits. Dopamine 53-55 cholecystokinin Homo sapiens 0-15 7640325-1 1995 Cholecystokinin (CCK) is co-localized with dopamine (DA) in neurons of the mesolimbic-frontocortical dopamine (DA) system, considered essential for the pathology of psychotic behavior and associated attention deficits. Dopamine 53-55 cholecystokinin Homo sapiens 17-20 7640325-1 1995 Cholecystokinin (CCK) is co-localized with dopamine (DA) in neurons of the mesolimbic-frontocortical dopamine (DA) system, considered essential for the pathology of psychotic behavior and associated attention deficits. Dopamine 101-109 cholecystokinin Homo sapiens 0-15 7640325-1 1995 Cholecystokinin (CCK) is co-localized with dopamine (DA) in neurons of the mesolimbic-frontocortical dopamine (DA) system, considered essential for the pathology of psychotic behavior and associated attention deficits. Dopamine 101-109 cholecystokinin Homo sapiens 17-20 7640325-1 1995 Cholecystokinin (CCK) is co-localized with dopamine (DA) in neurons of the mesolimbic-frontocortical dopamine (DA) system, considered essential for the pathology of psychotic behavior and associated attention deficits. Dopamine 111-113 cholecystokinin Homo sapiens 0-15 7640325-1 1995 Cholecystokinin (CCK) is co-localized with dopamine (DA) in neurons of the mesolimbic-frontocortical dopamine (DA) system, considered essential for the pathology of psychotic behavior and associated attention deficits. Dopamine 111-113 cholecystokinin Homo sapiens 17-20 8185154-0 1994 Cholecystokinin modulates dopamine-mediated behaviors. Dopamine 26-34 cholecystokinin Homo sapiens 0-15 7479342-1 1995 Cholecystokinin (CCK) has been localized in the nucleus accumbens (NAC) where it may interact with dopamine neurotransmission. Dopamine 99-107 cholecystokinin Homo sapiens 0-15 7479342-1 1995 Cholecystokinin (CCK) has been localized in the nucleus accumbens (NAC) where it may interact with dopamine neurotransmission. Dopamine 99-107 cholecystokinin Homo sapiens 17-20 8248241-3 1993 We report here that CCK-8S abolishes cAMP-dependent phosphorylation of a dopamine- and cAMP-regulated 32-kDa phosphoprotein (DARPP-32) in striatal neurons. Dopamine 73-81 cholecystokinin Homo sapiens 20-23 21776120-0 1992 Dopamine and obsessive disorder: a clinical study with cck and methyl phenidate. Dopamine 0-8 cholecystokinin Homo sapiens 55-58 7987278-5 1993 This new example of functional plasticity suggests that dopamine exerts a negative tonus on cholecystokinin expression. Dopamine 56-64 cholecystokinin Homo sapiens 92-107 1792008-5 1991 Systemic treatment with CCK receptor antagonists is likely to influence both GABA- and dopamine-linked CCK-ergic neurotransmission, and therefore their effects in exploratory activity tests should be interpreted with caution. Dopamine 87-95 cholecystokinin Homo sapiens 24-27 1611514-10 1992 These results suggest a differential role of CCK receptor subtypes on reward-related behaviour and complement previous studies suggesting bimodal effects of CCK systems on mesolimbic dopamine function. Dopamine 183-191 cholecystokinin Homo sapiens 157-160 1686250-4 1991 CCK-8S has been shown to coexist with neurotensin and dopamine in neurons projecting from the ventral tegmental area to the nucleus accumbens, and to a lesser extent in neurons of the substantia nigra projecting to periventricular regions of the caudate. Dopamine 54-62 cholecystokinin Homo sapiens 0-3 2048219-0 1991 Cholecystokinin-dopamine interactions. Dopamine 16-24 cholecystokinin Homo sapiens 0-15 2048219-2 1991 In this review Jacki Crawley integrates the neurophysiological, behavioral, and release studies which demonstrate both excitatory effects of CCK, and facilitatory modulating effects of CCK on the inhibitory actions of dopamine, in the mesolimbic pathway. Dopamine 218-226 cholecystokinin Homo sapiens 185-188 1792008-5 1991 Systemic treatment with CCK receptor antagonists is likely to influence both GABA- and dopamine-linked CCK-ergic neurotransmission, and therefore their effects in exploratory activity tests should be interpreted with caution. Dopamine 87-95 cholecystokinin Homo sapiens 103-106 2688364-0 1989 Presence of cholecystokinin mRNA in dopamine cells in the ventral mesencephalon of a human with schizophrenia. Dopamine 36-44 cholecystokinin Homo sapiens 12-27 1956989-2 1991 Cholecystokinin (CCK) is a neuropeptide which is co-localized within some mesolimbic and mesocortical dopamine neurons. Dopamine 102-110 cholecystokinin Homo sapiens 0-15 1956989-2 1991 Cholecystokinin (CCK) is a neuropeptide which is co-localized within some mesolimbic and mesocortical dopamine neurons. Dopamine 102-110 cholecystokinin Homo sapiens 17-20 1978324-0 1990 Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and in humans with schizophrenia. Dopamine 45-53 cholecystokinin Homo sapiens 26-41 2274639-4 1990 CCK appears to be required for neuroleptic-induced depolarization-inactivation of dopamine neurons and associated antipsychotic response; therefore, schizophrenic patients with low CCK may be resistant to the antipsychotic effects of neuroleptics. Dopamine 82-90 cholecystokinin Homo sapiens 0-3 33794246-7 2021 CCK modulates DA release in the nucleus accumbens (NAc) and it is expressed in the gamma-aminobutyric acid (GABA)-expressing basket interneurons in the cerebral cortex. Dopamine 14-16 cholecystokinin Homo sapiens 0-3 33794246-10 2021 Given the "dimmer-switch" function of endogenous CCK in the neurotransmission by 5-HT, DA, GABA, and glutamate in normal and pathological behaviors (Ballaz and Bourin, 2020), we hypothesize that CCK adjusts functioning of the reward and anxiety circuitries altered by ethanol. Dopamine 87-89 cholecystokinin Homo sapiens 49-52 3318183-4 1987 New aspects of the CCK research are concentrated on interaction with other transmitter systems especially with the dopamine and opioid system. Dopamine 115-123 cholecystokinin Homo sapiens 19-22 2765186-3 1989 Results indicate that rostral Acc CCK microinjections have dopamine antagonistlike effects and caudal Acc CCK microinjections have dopamine agonistlike effects on amphetamine-induced locomotor activity. Dopamine 131-139 cholecystokinin Homo sapiens 106-109 2765186-4 1989 The relevance of the present findings to previous results regarding CCK-dopamine interactions is discussed. Dopamine 72-80 cholecystokinin Homo sapiens 68-71 2918999-5 1989 The dopamine antagonist-like effects of CCK appear to involve CCK actions in the more rostral regions of the NA and may reflect the contribution of non-dopamine neuron-derived source(s) of CCK. Dopamine 4-12 cholecystokinin Homo sapiens 40-43 2918999-5 1989 The dopamine antagonist-like effects of CCK appear to involve CCK actions in the more rostral regions of the NA and may reflect the contribution of non-dopamine neuron-derived source(s) of CCK. Dopamine 4-12 cholecystokinin Homo sapiens 62-65 2918999-5 1989 The dopamine antagonist-like effects of CCK appear to involve CCK actions in the more rostral regions of the NA and may reflect the contribution of non-dopamine neuron-derived source(s) of CCK. Dopamine 4-12 cholecystokinin Homo sapiens 62-65 2546180-8 1989 These data are consistent with the pharmacology for CCK inhibition of dopamine release in the striatum; suggesting that CCK effects on cerebellar cGMP may be mediated by antidopaminergic actions within this striatum. Dopamine 70-78 cholecystokinin Homo sapiens 52-55 3208120-1 1988 Intravenous administration of the cholecystokinin (CCK) antagonist lorglumide (LORG) reversed chronic haloperidol (CHAL)-induced depolarization inactivation (DI) of dopamine (DA) cells in both the A9 and A10 areas. Dopamine 165-173 cholecystokinin Homo sapiens 51-54 3208120-1 1988 Intravenous administration of the cholecystokinin (CCK) antagonist lorglumide (LORG) reversed chronic haloperidol (CHAL)-induced depolarization inactivation (DI) of dopamine (DA) cells in both the A9 and A10 areas. Dopamine 175-177 cholecystokinin Homo sapiens 51-54 3614556-1 1987 The anatomical distribution of cholecystokinin (CCK)-dopamine (DA) neurons suggests that CCK could modulate dopaminergic activity. Dopamine 53-61 cholecystokinin Homo sapiens 31-46 3037032-0 1987 Cholecystokinin stimulates dopamine synthesis in synaptosomes by a cyclic AMP-dependent mechanism. Dopamine 27-35 cholecystokinin Homo sapiens 0-15 3037032-1 1987 The effects of different fragments of cholecystokinin (CCK) on dopamine synthesis were studied in synaptosomal preparations from the striatum, substantia nigra, and frontal cortex. Dopamine 63-71 cholecystokinin Homo sapiens 55-58 3037032-7 1987 In all three regions, CCK-5 and high K+ had an additive effect on dopamine synthesis; CCK-5 and 8-Br-cyclic AMP together produced the same enhancement of synthesis as CCK-5 alone. Dopamine 66-74 cholecystokinin Homo sapiens 22-25 3037032-8 1987 CCK-5 produced similar dose-dependent increases in dopamine synthesis and cyclic AMP accumulation in striatal synaptosomes, and both effects were blocked by the CCK antagonist proglumide. Dopamine 51-59 cholecystokinin Homo sapiens 0-3 3614556-1 1987 The anatomical distribution of cholecystokinin (CCK)-dopamine (DA) neurons suggests that CCK could modulate dopaminergic activity. Dopamine 53-61 cholecystokinin Homo sapiens 48-51 3614556-1 1987 The anatomical distribution of cholecystokinin (CCK)-dopamine (DA) neurons suggests that CCK could modulate dopaminergic activity. Dopamine 53-61 cholecystokinin Homo sapiens 89-92 4009236-1 1985 Cholecystokinin (CCK), one of the most common brain peptides, coexists with dopamine (DA) in neurons of the medial substantia nigra (SN). Dopamine 76-84 cholecystokinin Homo sapiens 0-15 4040554-0 1985 Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence. Dopamine 28-36 cholecystokinin Homo sapiens 0-15 4040554-1 1985 Cholecystokinin coexists with dopamine in mesolimbic neurons in mammalian brain. Dopamine 30-38 cholecystokinin Homo sapiens 0-15 4040554-2 1985 When injected directly into the nucleus accumbens, cholecystokinin (CCK) potentiated dopamine (DA)-induced hyperlocomotion and apomorphine-induced stereotypy. Dopamine 85-93 cholecystokinin Homo sapiens 51-66 4040554-2 1985 When injected directly into the nucleus accumbens, cholecystokinin (CCK) potentiated dopamine (DA)-induced hyperlocomotion and apomorphine-induced stereotypy. Dopamine 85-93 cholecystokinin Homo sapiens 68-71 4040554-2 1985 When injected directly into the nucleus accumbens, cholecystokinin (CCK) potentiated dopamine (DA)-induced hyperlocomotion and apomorphine-induced stereotypy. Dopamine 95-97 cholecystokinin Homo sapiens 51-66 4040554-2 1985 When injected directly into the nucleus accumbens, cholecystokinin (CCK) potentiated dopamine (DA)-induced hyperlocomotion and apomorphine-induced stereotypy. Dopamine 95-97 cholecystokinin Homo sapiens 68-71 4040554-6 1985 Facilitation of DA-mediated behaviors by CCK may represent a functional interaction specific to the neuromodulator-neurotransmitter coexistence phenomenon. Dopamine 16-18 cholecystokinin Homo sapiens 41-44 2819952-0 1987 Cholecystokinin-induced inhibition of dopamine neurotransmission: comparison with chronic haloperidol treatment. Dopamine 38-46 cholecystokinin Homo sapiens 0-15 4009236-1 1985 Cholecystokinin (CCK), one of the most common brain peptides, coexists with dopamine (DA) in neurons of the medial substantia nigra (SN). Dopamine 76-84 cholecystokinin Homo sapiens 17-20 4009236-1 1985 Cholecystokinin (CCK), one of the most common brain peptides, coexists with dopamine (DA) in neurons of the medial substantia nigra (SN). Dopamine 86-88 cholecystokinin Homo sapiens 0-15 6320923-1 1983 By means of the dopamine (DA) agonist radio ligand 3H-N-propylnorapomorphine (3H-NPA) the effects of cholecystokinin-8 (CCK-8) have been evaluated in vitro on the binding characteristics of the DA agonist sites in membrane preparations from the subcortical limbic forebrain containing mainly nucleus accumbens and tuberculum olfactorium. Dopamine 16-24 cholecystokinin Homo sapiens 120-123 3737785-1 1986 Cholecystokinin (CCK), a neuropeptide which fulfills almost all criteria for neurotransmitter status, has been co-localized with dopamine in midbrain mesolimbic and mesocortical neurons that have been implicated in the pathogenesis of schizophrenia. Dopamine 129-137 cholecystokinin Homo sapiens 0-15 3737785-1 1986 Cholecystokinin (CCK), a neuropeptide which fulfills almost all criteria for neurotransmitter status, has been co-localized with dopamine in midbrain mesolimbic and mesocortical neurons that have been implicated in the pathogenesis of schizophrenia. Dopamine 129-137 cholecystokinin Homo sapiens 17-20 4080706-1 1985 Cholecystokinin octapeptide sulfate (CCK) injected bilaterally into the nucleus accumbens significantly potentiated dopamine-induced hyperlocomotion and apomorphine-induced stereotypy. Dopamine 116-124 cholecystokinin Homo sapiens 37-40 6145498-4 1984 Dopamine (DA) decreased the firing of NAc cells and reversed CCK-induced excitation. Dopamine 0-8 cholecystokinin Homo sapiens 61-64 6145498-4 1984 Dopamine (DA) decreased the firing of NAc cells and reversed CCK-induced excitation. Dopamine 10-12 cholecystokinin Homo sapiens 61-64 6695625-0 1984 Extrapyramidal dopamine regulation by cholecystokinin and its role in Parkinson"s disease. Dopamine 15-23 cholecystokinin Homo sapiens 38-53 4080706-4 1985 Unsulfated CCK had no effect alone or in conjunction with dopamine or apomorphine, suggesting that the facilitory effect of CCK on dopamine-mediated behaviors is specific for the sulfated form of CCK. Dopamine 131-139 cholecystokinin Homo sapiens 124-127 4080706-4 1985 Unsulfated CCK had no effect alone or in conjunction with dopamine or apomorphine, suggesting that the facilitory effect of CCK on dopamine-mediated behaviors is specific for the sulfated form of CCK. Dopamine 131-139 cholecystokinin Homo sapiens 124-127 6321698-6 1984 The findings suggest that CCK-8 sulfate in dopamine/CCK coexistence regions is involved in regulating dopamine release. Dopamine 43-51 cholecystokinin Homo sapiens 26-29 6321698-6 1984 The findings suggest that CCK-8 sulfate in dopamine/CCK coexistence regions is involved in regulating dopamine release. Dopamine 43-51 cholecystokinin Homo sapiens 52-55 6321698-6 1984 The findings suggest that CCK-8 sulfate in dopamine/CCK coexistence regions is involved in regulating dopamine release. Dopamine 102-110 cholecystokinin Homo sapiens 26-29 6321698-6 1984 The findings suggest that CCK-8 sulfate in dopamine/CCK coexistence regions is involved in regulating dopamine release. Dopamine 102-110 cholecystokinin Homo sapiens 52-55 6694511-1 1984 The close relationship of cholecystokinin peptides with some of the dopamine pathways and the limbic system suggests a putative role for these peptides in the pathophysiology of neuropsychiatric disorders such as Parkinson"s disease, manic-depression and schizophrenia. Dopamine 68-76 cholecystokinin Homo sapiens 26-41 19793020-1 2009 The nicotine metabolism of CYP2A6 (CYP2A6*1A,*1B, and *1C), and the cholecystokinin (CCK; which modulates the release of dopamine) and CCK-A receptor gene and personality traits for NEO-FFI, was investigated for the mechanism for elucidation of the smoking behavior in Japanese populations. Dopamine 121-129 cholecystokinin Homo sapiens 68-83 6159653-7 1980 Of particular interest is the occurrence of VIP in presumed cholinergic neurons innervating exocrine glands in the cat, and the coexistence of a cholecystokinin (CCK)-like peptide in dopamine neurons projecting mainly to limbic areas. Dopamine 183-191 cholecystokinin Homo sapiens 145-160 6159653-7 1980 Of particular interest is the occurrence of VIP in presumed cholinergic neurons innervating exocrine glands in the cat, and the coexistence of a cholecystokinin (CCK)-like peptide in dopamine neurons projecting mainly to limbic areas. Dopamine 183-191 cholecystokinin Homo sapiens 162-165 19793020-1 2009 The nicotine metabolism of CYP2A6 (CYP2A6*1A,*1B, and *1C), and the cholecystokinin (CCK; which modulates the release of dopamine) and CCK-A receptor gene and personality traits for NEO-FFI, was investigated for the mechanism for elucidation of the smoking behavior in Japanese populations. Dopamine 121-129 cholecystokinin Homo sapiens 85-88 15837012-1 2005 Cholecystokinin (CCK), a neurotransmitter in the central nervous system (CNS), co-exists in a large portion of A10 dopamine neurons to exert some effect on dopamine behavior. Dopamine 115-123 cholecystokinin Homo sapiens 0-15 15837012-1 2005 Cholecystokinin (CCK), a neurotransmitter in the central nervous system (CNS), co-exists in a large portion of A10 dopamine neurons to exert some effect on dopamine behavior. Dopamine 115-123 cholecystokinin Homo sapiens 17-20 15837012-1 2005 Cholecystokinin (CCK), a neurotransmitter in the central nervous system (CNS), co-exists in a large portion of A10 dopamine neurons to exert some effect on dopamine behavior. Dopamine 156-164 cholecystokinin Homo sapiens 0-15 15837012-1 2005 Cholecystokinin (CCK), a neurotransmitter in the central nervous system (CNS), co-exists in a large portion of A10 dopamine neurons to exert some effect on dopamine behavior. Dopamine 156-164 cholecystokinin Homo sapiens 17-20 15740988-1 2005 We analyzed genetic variants of the promoter region of the cholecystokinin (CCK; which modulates the release of dopamine) gene, and intron 1 and exon 5 of the CCKA receptor gene, and performed association analyses of nicotine dependence using an allele-specific amplification (ASA) method and PCR-RFLP methods. Dopamine 112-120 cholecystokinin Homo sapiens 59-74 15740988-1 2005 We analyzed genetic variants of the promoter region of the cholecystokinin (CCK; which modulates the release of dopamine) gene, and intron 1 and exon 5 of the CCKA receptor gene, and performed association analyses of nicotine dependence using an allele-specific amplification (ASA) method and PCR-RFLP methods. Dopamine 112-120 cholecystokinin Homo sapiens 76-79 17109076-5 2007 Given that CCK is a modulator of dopamine in the reward process, the increase in CCK-8S and CCK-4 is not unexpected. Dopamine 33-41 cholecystokinin Homo sapiens 11-14 17365745-1 2007 In view of the effect of cholecystokinin (CCK) on dopaminergic neurons in the mesolimbic "reward" pathway of the brain, its gene has been a focus in studies of dopamine-related conditions and behaviors, including smoking. Dopamine 50-58 cholecystokinin Homo sapiens 25-40 17365745-1 2007 In view of the effect of cholecystokinin (CCK) on dopaminergic neurons in the mesolimbic "reward" pathway of the brain, its gene has been a focus in studies of dopamine-related conditions and behaviors, including smoking. Dopamine 50-58 cholecystokinin Homo sapiens 42-45 16738800-3 2006 Preliminary data suggest that involvement of CCK and its receptor subtypes in anxiety can be better described when focusing on distinct endophenotypes, and considering environmental contingencies and confounds originating from interactions with dopamin-, opioid- and glutamatergic neurotransmission. Dopamine 245-252 cholecystokinin Homo sapiens 45-48